Aethlon Medical, Inc. (AEMD): Price and Financial Metrics

Aethlon Medical, Inc. (AEMD): $0.68

-0.03 (-4.75%)

POWR Rating

Component Grades














  • AEMD scores best on the Sentiment dimension, with a Sentiment rank ahead of 87.44% of US stocks.
  • The strongest trend for AEMD is in Quality, which has been heading down over the past 58 days.
  • AEMD's current lowest rank is in the Stability metric (where it is better than 3.06% of US stocks).

AEMD Stock Summary

  • AEMD has a higher market value than merely 5.98% of US stocks; more precisely, its current market capitalization is $21,938,199.
  • With a price/sales ratio of 135.25, AETHLON MEDICAL INC has a higher such ratio than 97.87% of stocks in our set.
  • Revenue growth over the past 12 months for AETHLON MEDICAL INC comes in at -79.5%, a number that bests merely 1.72% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AETHLON MEDICAL INC are IDEX, PUMP, CVLG, MLP, and MEC.
  • AEMD's SEC filings can be seen here. And to visit AETHLON MEDICAL INC's official web site, go to

AEMD Valuation Summary

  • AEMD's price/sales ratio is 137.7; this is 6159.09% higher than that of the median Healthcare stock.
  • Over the past 87 months, AEMD's price/earnings ratio has gone up 8.

Below are key valuation metrics over time for AEMD.

Stock Date P/S P/B P/E EV/EBIT
AEMD 2022-09-09 137.7 1.5 -2.0 -0.7
AEMD 2022-09-08 134.6 1.4 -1.9 -0.7
AEMD 2022-09-07 129.0 1.4 -1.9 -0.6
AEMD 2022-09-06 137.0 1.5 -2.0 -0.7
AEMD 2022-09-02 141.4 1.5 -2.0 -0.7
AEMD 2022-09-01 138.9 1.5 -2.0 -0.7

AEMD Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -68.14%.
  • The 2 year net cashflow from operations growth rate now stands at -87.92%.
  • Its 5 year revenue growth rate is now at -27.58%.
AEMD's revenue has moved up $52,199 over the prior 33 months.

The table below shows AEMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.162199 -10.42425 -11.22528
2022-03-31 0.294165 -9.767157 -10.41609
2021-12-31 0.315282 -8.90671 -8.893984
2021-09-30 0.923036 -8.386 -8.811144
2021-06-30 0.79107 -7.734795 -8.573729
2021-03-31 0.659104 -6.76494 -7.886709

AEMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEMD has a Quality Grade of D, ranking ahead of 11.25% of graded US stocks.
  • AEMD's asset turnover comes in at 0.049 -- ranking 72nd of 75 Measuring and Control Equipment stocks.
  • FCUV, SYPR, and SENS are the stocks whose asset turnover ratios are most correlated with AEMD.

The table below shows AEMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.049 1 11.337
2021-03-31 0.048 1 10.363
2020-12-31 0.061 1 11.087
2020-09-30 0.053 1 11.287
2020-06-30 0.076 1 13.238
2020-03-31 0.135 1 15.993

AEMD Price Target

For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.5 (Moderate Buy)

AEMD Stock Price Chart Interactive Chart >

Price chart for AEMD

AEMD Price/Volume Stats

Current price $0.68 52-week high $4.58
Prev. close $0.71 52-week low $0.62
Day low $0.62 Volume 343,000
Day high $0.71 Avg. volume 1,652,957
50-day MA $1.14 Dividend yield N/A
200-day MA $1.33 Market Cap 11.32M

Aethlon Medical, Inc. (AEMD) Company Bio

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.

AEMD Latest News Stream

Event/Time News Detail
Loading, please wait...

AEMD Latest Social Stream

Loading social stream, please wait...

View Full AEMD Social Stream

Latest AEMD News From Around the Web

Below are the latest news stories about AETHLON MEDICAL INC that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies

Yahoo | September 12, 2022

Aethlon Medical to Present at Two Investor Conferences in September

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conferences in September. These include the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York from Sept. 12-14, 2022, and the Life Sciences Investor Forum, being held virtually on Sept. 15, 2022. At both conferences, Steven La

Yahoo | September 6, 2022

AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expanding the Potential Indications for Hemopurifier Treatment Aethlon Medical’s (NASDAQ:AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro

Yahoo | August 17, 2022

Aethlon Medical, Inc. (NASDAQ:AEMD) Is About To Turn The Corner

With the business potentially at an important milestone, we thought we'd take a closer look at Aethlon Medical, Inc.'s...

Yahoo | August 15, 2022

H.C. Wainwright Keeps Their Buy Rating on Aethlon Medical (AEMD)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Aethlon Medical (AEMD - Research Report) today and set a price target of $9.00. The company's shares opened today at $1.32.According to TipRanks, Bernardino is a 5-star analyst with an average return of 25.2% and a 36.60% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Achieve Life Sciences, and Seres Therapeutics.Aethlon Medical has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, representing a 392.42% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.

Howard Kim on TipRanks | August 11, 2022

Read More 'AEMD' Stories Here

AEMD Price Returns

1-mo -40.87%
3-mo -35.85%
6-mo -53.74%
1-year -83.81%
3-year -80.80%
5-year -96.94%
YTD -63.44%
2021 -24.70%
2020 156.49%
2019 -96.13%
2018 46.90%
2017 -73.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6057 seconds.